Bcr and Abl interaction: Oncogenic activation of c-Abl by sequestering Bcr

Cancer Research

Volumn 63, Issue 2, 2003, Pages 298-303

  Ling, Xiaoyang ^a   Ma, Guozhen ^a   Sun, Tong ^a   Liu, Jiaxin ^a   Arlinghaus, Ralph B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; IMATINIB; ONCOPROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CELL STRAIN COS1; CONTROLLED STUDY; ENZYME ACTIVATION; GENE ACTIVATION; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; ONCOGENE PROTEINS; ONCOGENE PROTEINS V-ABL; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-BCR; RATS; SRC HOMOLOGY DOMAINS; TRANSFECTION;

EID: 0037439960     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Wang, J. Y. J. Abl tyrosine kinase in signal transduction and cell cycle regulation. Curr. Opin. Genet. Dev., 3: 35-43, 1993.
2. Van Etten, R. A., Jackson, P., and Baltimore, D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell, 58: 669-678, 1989.
3. Van Etten, R. A., Jackson, P. K., Baltimore, D., Sanders, M. C., Matsudaira, P. T., and Janmey, P. A. The COOH terminus of the c-Abl tyrosine kinase contains distinct F-and G-actin binding domains and bundling activity. J. Cell Biol., 124: 325-340, 1994.
4. Pendergast, A. M., Muller, A. J., Havlik, M. H., Clark, R., McCormick, F., and Witte, O. N. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc. Natl. Acad. Sci. USA, 88: 5927-5931, 1991.
5. Plattner, R., Kadlec, L., DeMali, K. A., Kazlauskas, A., and Pendergast, A. M. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 13: 2400-2411, 1999.
6. Ma, G., Lu, D., Wu, Y., Liu, J., and Arlinghaus, R. B. Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene, 14: 2367-2372, 1997.
7. Pendergast, A. M., Muller, A. J., Havlik, M. H., Maru, Y., and Witte, O. N. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a nonphosphotyrosine-dependent manner. Cell, 66: 161-171, 1991.
8. Hawk, N., Liu, J., Sun, T., Wang, Y., Wu, Y., and Arlinghaus, R. B. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. Cancer Res., 62: 386-390, 2002.
9. Songyang, Z., Carraway, K. L., III, Eck, M. J., Harrison, S. C., Feldman, R. A., Mohammadi, M., Schlessinger, J., Hubbard, S. R., Smith, D. P., Lorenzo, M. J., Ponder, B. A. J., Mayer, B. J., and Cantley, L. C. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature (Lond.), 373: 536-539, 1995.
10. Guo, J. Q., Lian, J. Y., Xian, Y. M., Lee, M-S., Deisseroth, A. B., Stass, S. A., Champlin, R. E., Talpaz, M., Wang, J. Y. J., and Arlinghaus, R. B. BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood, 83: 3629-3637, 1994.
11. Shtivelman, E., Lifshitz, B., Gale, R. P., Roe, B. A., and Canaani, E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell, 47: 277-284, 1986.
12. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D. In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science (Wash. DC), 272: 263-266, 1996.
13. Iwakuma, T., Cui, Y., and Chang, L. J. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology, 261: 120-132, 1999.
14. Wu, Y., Ma, G., Lu, D., Lin, F., Xu, H-J., Liu, J., and Arlinghaus, R. B. Bcr: a negative regulator of the Bcr-Abl oncoprotein. Oncogene, 18: 4416-4424, 1999.
15. Bahnson, A. B., Dunigan, J. T., Baysal, B. E, Mohney, T., Atchinson, R. W., Nimgaonkar, M. T., Ball, E. D., and Barranger, J. A. Centrifugal enhancement of retroviral mediated gene transfer. J. Virol. Methods, 54: 131-143, 1995.
16. Liu, J., Wu, Y., Lu, D., Haataja, L., Heisterkamp, N., Groffen, J., and Arlinghaus, R. B. Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol. Cell. Biol., 16: 998-1005, 1996.
17. Liu, J., Wu, Y., and Arlinghaus, R. B. Sequences within the first exon of BCR inhibit the activated tyrosine kinase of c-Abl and the Bcr-Abl oncoprotein. Cancer Res 56: 5120-5124, 1996.
18. Lin, F., Liu, J., Monaco, G., Sun, T., Liu, J., Lin, H., Stephens, C., Belmont, J., and Arlinghaus, R. B. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model. Oncogene, 20: 1873-1881, 2001.
19. c subunit and constitutively induces its tyrosine phosphorylation. Cancer Res., 56: 3426-3430, 1996.
20. Lugo, T. G., and Witte, O. N. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol. Cell. Biol., 9: 1263-1270, 1989.
21. Mayer, B. J., Jackson, P. K., Van Etten, R. A., and Baltimore, D. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol. Cell. Biol., 12: 609-618, 1992.
22. Lozzio, C. B., and Lozzio, B. B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood, 45: 321-334, 1975.
23. Druker, B. J., Tamura, S. Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2: 561-566, 1996.
24. Wu, Y., Liu, J., and Arlinghaus, R. B. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene, 16: 141-146, 1998.
25. Mayer, B. J., and Hanafusa, H. Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation. J. Virol., 64: 3581-3589, 1990.
26. Mayer, B. J., Hamaguchi, M., and Hanafusa, H. A novel viral oncogene with structural similarity to phospholipase C. Nature (Lond.), 332: 272-275, 1988.
27. Pluk, H., Dorey, K., and Superti-Furga, G. Autoinhibition of c-Abl. Cell, 108: 247-259, 2002.